-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Although chimeric antigen receptor (CAR) T cell therapy has achieved a high remission rate in patients with relapsed or refractory large B-cell lymphoma (LBCL), less than 40% of patients can maintain long-term remission
Although chimeric antigen receptor (CAR) T cell therapy has achieved a high remission rate in patients with relapsed or refractory large B-cell lymphoma (LBCL), less than 40% of patients can maintain long-term remission of lymphoma CAR- T management
Glucocorticoids are commonly used to manage the severe toxicity associated with CAR T cell therapy.
The newly published " Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma " in the "Blood" magazine explored the effects of glucocorticoids on the recurrence or recurrence of standard anti-CD19 CAR-T cell therapy.
Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma
A total of 100 patients were evaluated, of which 60 (60%) received glucocorticoid therapy to manage toxic reactions related to CAR-T cell therapy
Effect of glucocorticoid on PFS and OS of patients
Effect of glucocorticoid on PFS and OS of patientsAfter a median follow-up of 10 months, a higher cumulative dose of glucocorticoids was associated with a significantly shorter progression-free survival
A higher cumulative dose of glucocorticoids is associated with a significantly shortened progression-free survival.
When managing the toxicity related to CAR-T cell therapy, the use of glucocorticoids should be controlled at the lowest dose and shortest duration as much as possible, and their activation time should be postponed as much as possible in the clinically feasible situation.
Original source:
Strati Paolo,Ahmed Sairah,Furqan Fateeha et al.
Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma
in this message
